Genmab A/S (NASDAQ:GMAB) Earns “Buy” Rating from HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 75.01% from the company’s current price.

A number of other equities research analysts have also commented on GMAB. Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and raised their price target for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Truist Financial reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $48.50.

Genmab A/S Price Performance

Shares of GMAB opened at $28.57 on Tuesday. The company has a market capitalization of $18.89 billion, a P/E ratio of 29.76, a PEG ratio of 2.02 and a beta of 0.98. Genmab A/S has a one year low of $26.32 and a one year high of $42.72. The business’s 50 day simple moving average is $29.44 and its 200-day simple moving average is $29.97.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, sell-side analysts anticipate that Genmab A/S will post 1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in shares of Genmab A/S in the 3rd quarter valued at $27,000. Pinnacle Bancorp Inc. lifted its holdings in Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after acquiring an additional 749 shares in the last quarter. NBC Securities Inc. acquired a new position in Genmab A/S in the third quarter valued at about $37,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Genmab A/S by 86.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after acquiring an additional 498 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.